Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Rubi develops biotechnology solutions for sustainable manufacturing in the fashion and textiles industry. The company uses scientific innovation to reduce environmental impact from industrial manufacturing processes.
6 investors
Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases. The company focuses on novel therapeutic approaches for patients with rare respiratory conditions.
6 investors
Science Exchange provides operational infrastructure for life sciences R&D, connecting organizations, suppliers, and workflows to streamline contracting, compliance, onboarding, and financial coordination across the research ecosystem.
6 investors
6 investors
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
6 investors
Shiru uses AI and material science to discover natural proteins and ingredients for use in food, personal care, agriculture, and advanced materials, reducing traditional development timelines from 5-15 years to 1-2 years.
6 investors
SOPHiA GENETICS provides an AI-driven, cloud-based platform (SOPHiA DDM) that analyzes genomic data to help clinicians produce actionable insights for patients with cancer and rare disorders. Its solutions serve clinical and research labs in precision oncology, including CE-IVD diagnostic products available across Europe and other regions.
6 investors
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.
6 investors
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.
6 investors
Strados Labs builds wearable biosensors and a cloud platform that continuously capture and analyze respiratory data — including cough, spirometry, FeNO, and eCOA endpoints — in patients' daily lives. It combines AI detection with review by credentialed respiratory specialists to produce regulatory-grade, audit-ready evidence for pharma sponsors running decentralized clinical trials.
6 investors
SubjectWell operates a patient network that links individuals to clinical trials and connects them with healthcare providers and pharmaceutical sponsors. The company serves patients, clinical research organizations, and pharmaceutical companies seeking to recruit and retain participants for medical studies.
6 investors
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
6 investors
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
6 investors
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.
6 investors
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy. Its pipeline targets cancer and inflammatory diseases.
6 investors
Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.
6 investors
Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
6 investors
Teiko provides CLIA-validated high-dimensional cytometry services—including spectral flow and mass cytometry panels, blood preservation kits, gating, and a data analysis dashboard—for immune cell profiling in clinical trials. It serves pharmaceutical and clinical research teams running global Phase I-IV trials across the US, EU, and Australia.
6 investors
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.
6 investors
The EVERY Company produces animal-free egg proteins using a patented fermentation process, supplying functional protein ingredients to food companies. Its products, such as OvoPro, are marketed as animal-free, antibiotic-free, kosher, halal, and sustainable.
6 investors
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists. It also offers technical support centers and imaging data management platforms for core labs.
6 investors
6 investors
Turbine develops computational simulations of cells to accelerate drug discovery and development in oncology, using in silico predictions validated through wet lab experiments.
6 investors
Unity Biotechnology was a biotechnology company that is no longer operating. The page provides only wind-down contact information and does not describe the company's products or focus.
6 investors